Macrolides, Clindamycin, and Ketolides

Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases

Volumn 1, Issue , 2014, Pages 358-376.e6

  Sivapalasingam, Sumathi ^a   Steigbigel, Neal H ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b New York Veteran's Administration   (United States)

Author keywords

Azithromycin; Clarithromycin; Clindamycin; Erythromycin; Ketolides; Lincomycin macrolides; Lincosamides; Telithromycin

Indexed keywords

EID: 84944579401     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-4801-3.00029-1     Document Type: Chapter

References (427)

1. Leclercq R, Courvalin P Resistance to macrolides and related antibiotics in Streptococcus pneumoniae. Antimicrob Agents Chemother 2002, 46:2727-2734.
2. Allen N Effects of macrolide antibiotics on ribosome function. Macrolide Antibiotics 2002, 261-280. Birkhauser Verlag, Boston. W. Schonfeld, H.A. Kirst (Eds.).
3. Edelstein PH Pneumococcal resistance to macrolides, lincosamides, ketolides and streptomycin B agents: molecular mechanisms and resistance phenotypes. Clin Infect Dis 2004, 38(suppl 4):5322-5327.
4. Sutcliffe J, Leclercq R Mechanisms of resistance to macrolides, lincosamides, and ketolides. Macrolide Antibiotics 2002, 281-317. Birkhauser Verlag, Boston. W. Schonfeld, H.A. Kirst (Eds.).
5. Chittum HS, Champney WS Erythromycin inhibits the assembly of the large ribosomal subunit in growing Escherichia coli cells. Curr Microbiol 1995, 30:273-279.
6. Leclercq R, Courvalin P Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria. Antimicrob Agents Chemother 1991, 35:1273-1276.
7. Mao JC, Putterman M Accumulation in gram-positive and gram-negative bacteria as a mechanism of resistance to erythromycin. J Bacteriol 1968, 95:1111-1117.
8. Taubeneck U Susceptibility of Proteus mirabilis and its stable L-forms to erythromycin and other macrolides. Nature 1962, 196:195-196.
9. Ross JI, Eady EA, Cove JH, Baumberg S Minimal functional system required for expression of erythromycin resistance by msrA in Staphylococcus aureus RN4220. Gene 1996, 183:143-148.
10. Prunier AL, Malbruny B, Laurans M, et al. High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J Infect Dis 2003, 187:1709-1716.
11. Farrell DJ, Douthwaite S, Morrissey I, et al. Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 Study. Antimicrob Agents Chemother 2003, 47:1777-1783.
12. Leclercq R Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002, 34:482-492.
13. Leclercq R, Courvalin P Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother 1991, 35:1267-1272.
14. Shain CS, Amsden GW Telithromycin: the first of the ketolides. Ann Pharmacother 2002, 36:452-464.
15. Richter SS, Hellman KP, Beekmann SE, et al. Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003. Clin Infect Dis 2005, 41:599-608a.
16. Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother 1996, 40:2562-2566.
17. Haight T, Finland M Observations on mode of action of erythromycin. Proc Soc Exp Biol Med 1952, 81:188-193.
18. Haight T, Finland M The antibacterial action of erythromycin. Proc Soc Exp Biol Med 1952, 81:175-183.
19. Sabath L, Gerstein DA, Loder PB, et al. Excretion of erythromycin and its enhanced activity in urine against gram-negative bacilli with alkalinization. J Lab Clin Med 1968, 72:916-923.
20. Pankuch GA, Visalli MA, Jacobs MR, Appelbaum PC Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob Agents Chemother 1998, 42:624-630.
21. Canton R, Loza E, Morosini MI, Baquero F Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000. J Antimicrob Chemother 2002, 50(suppl S1):9-24.
22. Aracil B, Minambres M, Oteo J, et al. Susceptibility of strains of Streptococcus agalactiae to macrolides and lincosamides, phenotype patterns and resistance genes. Clin Microbiol Infect 2002, 8:745-748.
23. Zhanel GG, Walters M, Noreddin A, et al. The ketolides: a critical review. Drugs 2002, 62:1771-1804.
24. Alcaide F, Benitez MA, Carratala J, et al. In vitro activities of the new ketolide HMR 3647 (telithromycin) in comparison with those of eight other antibiotics against viridans group Streptococci isolated from blood of neutropenic patients with cancer. Antimicrob Agents Chemother 2001, 45:624-626.
25. Hoban DJ Prevalence and characterization of macrolide resistance in clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes from North America. J Chemother 2002, 14(suppl 3):25-30.
26. Samra Z, Rosenberg S, Soffer Y, Dan M In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines. Diagn Microbiol Infect Dis 2001, 39:177-179.
27. Edelstein PH, Edelstein MA In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. Antimicrob Agents Chemother 1999, 43:90-95.
28. Critchley IA, Jones ME, Heinze PD, et al. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infect 2002, 8:214-221.
29. Ednie LM, Jacobs MR, Appelbaum PC Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004). Antimicrob Agents Chemother 1997, 41:2019-2022.
30. Bermudez LE, Inderlied CB, Kolonoski P, et al. Telithromycin is active against Mycobacterium avium in mice despite lacking significant activity in standard in vitro and macrophage assays and is associated with low frequency of resistance during treatment. Antimicrob Agents Chemother 2001, 45:2210-2214.
31. Pfaller MA, Farrell DJ, Sader HS, et al. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Clin Infect Dis 2012, 55(suppl 3):S187-S193.
32. Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis 2002, 34(suppl 1):S4-S16.
33. Hyde TB, Gay K, Stephens DS, et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001, 286:1857-1862.
34. Hsueh PR, Liu CY, Luh KT Current status of antimi-crobial resistance in Taiwan. Emerg Infect Dis 2002, 8:132-137.
35. Martin JM, Green M, Barbadora KA, Wald ER Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. N Engl J Med 2002, 346:1200-1206.
36. Farrell DJ, File TM, Jenkins SG Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000-2004) of the PROTEKT US Study. J Clin Micro 2007, 45:290-293.
37. Thornsberry C, Ogilvie PT, Holley HP, Sahm DF Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study. Antimicrob Agents Chemother 1999, 43:2612-2623.
38. Ednie LM, Visalli MA, Jacobs MR, Appelbaum PC Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci. Antimicrob Agents Chemother 1996, 40:1950-1952.
39. Sutcliffe J, Tait-Kamradt A, Wondrack L Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother 1996, 40:1817-1824.
40. Gay K, Baughman W, Miller Y, et al. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment. J Infect Dis 2000, 182:1417-1424.
41. Corso A, Severina EP, Petruk VF, et al. Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States. Microb Drug Resist 1998, 4:325-337.
42. Jenkins SG, Brown SD, Farrell DJ Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Ann Clin Microbiol and Antimicrobials 2008, 7:1.
43. Lagrou K, Peetermans WE, Verhaegen J, et al. Macrolide resistance in Belgian Streptococcus pneumoniae. J Antimicrob Chemother 2000, 45:119-121.
44. Wang M, Zhang Y, Zhu D, Wang F Prevalence and phenotypes of erythromycin-resistant Streptococcus pneumoniae in Shanghai, China. Diagn Microbiol Infect Dis 2001, 39:187-189.
45. Lowbury E, Hurst L The sensitivity of staphylococci and other wound bacteria to erythromycin, oleandomycin and spiramycin. J Clin Pathol 1959, 12:163-164.
46. Hsueh PR, Teng LJ, Lee LN, et al. Increased prevalence of erythromycin resistance in streptococci: substantial upsurge in erythromycin-resistant M phenotype in Streptococcus pyogenes (1979-1998) but not in Streptococcus pneumoniae (1985-1999) in Taiwan. Microb Drug Resist 2002, 8:27-33.
47. Gordon KA, Beach ML, Biedenbach DJ, et al. Antimicrobial susceptibility patterns of beta-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis 2002, 43:157-162.
48. Avanzini C, Bosio K, Volpe G, et al. Streptococcus pyogenes collected in Torino (northwest Italy) between 1983 and 1998: survey of macrolide resistance and trend of genotype by RAPD. Microb Drug Resist 2000, 6:289-295.
49. Alos JI, Aracil B, Oteo J, et al. High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in 1998. Spanish Group for the Study of Infection in the Primary Health Care Setting. J Antimicrob Chemother 2000, 45:605-609.
50. Green MD, Beall B, Marcon MJ, et al. Multicentre surveillance of the prevalence and molecular epidemiology of macrolide resistance among pharyngeal isolates of group A streptococci in the USA. J Antimicrobial Chemotherapy 2006, 57:1240-1243.
51. Villasenor-Sierra A, Katahira E, Jaramillo-Valdivia AN, et al. Phenotypes and genotypes of erythromycin-resistant pyogenes strains isolated from invasive and non-invasive infections from Mexico and the USA during 1999-2010. Int J Infect Dis 2012, 16:e178-e181.
52. Seppala H, Nissinen A, Jarvinen H, et al. Resistance to erythromycin in group A streptococci. N Engl J Med 1992, 326:292-297.
53. Seppala H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997, 337:441-446.
54. Westh H, Rosdahl VT, Friis H Erythromycin resistance in Danish Staphylococcus aureus hospital strains with emphasis on erythromycin consumption. APMIS 1989, 97:1121-1124.
55. Pfaller MA, Jones RN, Doern GV, et al. Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group. Diagn Microbiol Infect Dis 1999, 33:283-297.
56. Schmitz FJ, Verhoef J, Fluit AC Prevalence of resistance to MLS antibiotics in 20 European university hospitals participating in the European SENTRY surveillance programme. Sentry Participants Group. J Antimicrob Chemother 1999, 43:783-792.
57. Sader HS, Flamm RK, Farrell DJ, et al. Activity analyses of Staphylococcal isolates from pediatric, adult and elderly patients: AWARE Ceftaroline surveillance program. Clin Infect Dis 2012, 55:S181-S186.
58. Lepper M, Dowling HF, Jackson GG, et al. Effect of antibiotic usage in the hospital on the incidence of antibiotic-resistant strains among personnel carrying staphylococci. J Lab Clin Med 1953, 42:832.
59. Haight TH, Finland FM Laboratory and clinical studies on erythromycin. N Engl J Med 1952, 247:227-232.
60. Garrod L The erythromycin group of antibiotics. Br Med J 1957, 2:57-63.
61. Pfaller MA, Mendes RE, Sader HS, Jones RN Telavancin activity against gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia. J Antimicrob Chemother 2010, 65:2396-2404.
62. Engler KH, Warner M, George RC In vitro activity of ketolides HMR 3004 and HMR 3647 and seven other antimicrobial agents against Corynebacterium diphtheriae. J Antimicrob Chemother 2001, 47:27-31.
63. Hof H, Nichterlein T, Kretschmar M Management of listeriosis. Clin Microbiol Rev 1997, 10:345-357.
64. Citron DM, Appleman MD Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria. Antimicrob Agents Chemother 2001, 45:345-348.
65. Goldstein EJ, Citron DM, Merriam CV, et al. Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes. Antimicrob Agents Chemother 1999, 43:2801-2805.
66. Finland M, Bach MC, Garner C, Gold O Synergistic action of ampicillin and erythromycin against Nocardia asteroides: effect of time of incubation. Antimicrob Agents Chemother 1974, 5:344-353.
67. Rapp RP, McCraney SA, Goodman NL, Shaddick DJ New macrolide antibiotics: usefulness in infections caused by mycobacteria other than Mycobacterium tuberculosis. Ann Pharmacother 1994, 28:1255-1263.
68. Wilson KE, Cassiday PK, Popovic T, Sanden GN Bordetella pertussis isolates with a heterogeneous phenotype for erythromycin resistance. J Clin Microbiol 2002, 40:2942-2944.
69. Angyo IA, Okpeh ES Changing patterns of antibiotic sensitivity and resistance during an outbreak of meningococcal infection in Jos, Nigeria. J Trop Pediatr 1998, 44:263-265.
70. Nilius AM, Bui MH, Almer L, et al. Comparative in vitro activity of ABT-773, a novel antibacterial ketolide. Antimicrob Agents Chemother 2001, 45:2163-2168.
71. Centers for Disease Control and Prevention Sexually Transmitted Disease Surveillance 2001 Supplement: Gonococcal Isolate Surveillance Project (GISP) Annual Report, 2001 2002, U.S. Department of Health and Human Services, Atlanta, Georgia.
72. Lewis K, Saubolle MA, Tenover FC, et al. Pertussis caused by an erythromycin-resistant strain of Bordetella pertussis. Pediatr Infect Dis J 1995, 14:388-391.
73. Centers for Disease Control and Prevention National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): Human Isolates Final Report, 2004 2007, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, Georgia.
74. Ednie LM, Spangler SK, Jacobs MR, Appelbaum PC Antianaerobic activity of the ketolide RU 64004 compared to activities of four macrolides, five beta-lactams, clindamycin, and metronidazole. Antimicrob Agents Chemother 1997, 41:1037-1041.
75. Kenny GE, Cartwright FD Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother 2001, 45:2604-2608.
76. Roblin PM, Reznik T, Kutlin A, Hammerschlag MR In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother 1999, 43:2806-2807.
77. Jao RL Susceptibility of Mycoplasma pneumoniae to 21 antibiotics in vitro. Am J Med Sci 1967, 253:639-650.
78. Matsuoka M, Narita N, Okazaki H, et al. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob Agents Chemother 2004, 48:4624-4630.
79. Wang Y, Qui S, Yang G, et al. An outbreak of Mycoplasma pneumoniae caused by a macrolide-resistant isolate in a nursery school in China. Antimicrob Agents Chemother 2012, 56:3748-3752.
80. Wolf BJ, Thacker l, Schwartz SB, et al. Detection of macrolide resistance in Mycoplasma pneumoniae by real time PCR and high resolution melt analysis. Antimicrob Agents Chemother 2008, 52:3542-3549.
81. Segreti J, Meyer P, Kapell K In vitro activity of macrolides against intracellular Legionella pneumophila. Diagn Microbiol Infect Dis 1996, 25:123-126.
82. Catnach SM, Fairclough PD Erythromycin and the gut. Gut 1992, 33:397-401.
83. Annese V, Lombardi G, Frusciante V, et al. Cisapride and erythromycin prokinetic effects in gastroparesis due to type 1 (insulin-dependent) diabetes mellitus. Aliment Pharmacol Ther 1997, 11:599-603.
84. Kendall BJ, Chakravarti A, Kendall E, et al. The effect of intravenous erythromycin on solid meal gastric emptying in patients with chronic symptomatic post-vagotomy-antrectomy gastroparesis. Aliment Pharmacol Ther 1997, 11:381-385.
85. Dive A, Miesse C, Galanti L, et al. Effect of erythromycin on gastric motility in mechanically ventilated critically ill patients: a double-blind, randomized, placebo-controlled study. Crit Care Med 1995, 23:1356-1362.
86. Nogami K, Nishikubo T, Minowa H, et al. Intravenous low-dose erythromycin administration for infants with feeding intolerance. Pediatr Int 2001, 43:605-610.
87. Bortolotti M, Annese V, Mari C, et al. Dose-related stimulatory effect of clarithromycin on interdigestive gastroduodenal motility. Digestion 2000, 62:31-37.
88. Maganti K, Onyemere K, Jones MP Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterology 2003, 98:259-263.
89. Kudoh S, Azuma A, Yamamoto M, et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998, 157:1829-1832.
90. Keicho N, Kudoh S Diffuse panbronchiolitis: the role of macrolides in therapy. Am J Resp Med 2002, 1:119-131.
91. Abdelghaffar H, Vazifeh D, Labro MT Erythromycin A-derived macrolides modify the functional activities of human neutrophils by altering the phospholipase D-phosphatidate phosphohydrolase transduction pathway: L-cladinose is involved both in alterations of neutrophil functions and modulation of this transductional pathway. J Immunol 1997, 159:3995-4005.
92. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000, 292:156-163.
93. Aoki Y, Kao PN Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells. Antimicrob Agents Chemother 1999, 43:2678-2684.
94. Desaki M, Takizawa H, Ohtoshi T, et al. Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun 2000, 267:124-128.
95. Yamamoto T, Kajikawa O, Martin TR, et al. The role of leukocyte emigration and IL-8 on the development of lipopolysaccharide-induced lung injury in rabbits. J Immunol 1998, 161:5704-5709.
96. Mikasa K, Kita E, Sawaki M, et al. The anti-inflammatory effect of erythromycin in zymosan-induced peritonitis of mice. J Antimicrob Chemother 1992, 30:339-348.
97. Li Y, Azuma A, Takahashi S, et al. Fourteen-membered ring macrolides inhibit vascular cell adhesion molecule 1 messenger RNA induction and leukocyte migration: role in preventing lung injury and fibrosis in bleomycin-challenged mice. Chest 2002, 122:2137-2145.
98. Shryock TR, Mortensen JE, Baumholtz M The effects of macrolides on the expression of bacterial virulence mechanisms. J Antimicrob Chemother 1998, 41:505-512.
99. Kucers A Chloramphenicol, erythromycin, vancomycin, tetracyclines. Lancet 1982, 2:425-429.
100. Bechtol L, Stephens VC, Pugh CT, et al. Erythromycin esters: comparative in vivo hydrolysis and bioavailability. Curr Ther Res 1976, 20:610-622.
101. Malmborg AS Effect of food on absorption of erythromycin: a study of two derivatives, the stearate and the base. J Antimicrob Chemother 1979, 5:591-599.
102. McDonald PJ, Mather LE, Story MJ Studies on absorption of a newly developed enteric-coated erythromycin base. J Clin Pharmacol 1977, 17:601-606.
103. Yakatan GJ, Rasmussen CE, Feis PJ, Wallen S Bioinequivalence of erythromycin ethylsuccinate and enteric-coated erythromycin pellets following multiple oral doses. J Clin Pharmacol 1985, 25:36-42.
104. DiSanto AR, Chodos DJ Influence of study design in assessing food effects on absorption of erythromycin base and erythromycin stearate. Antimicrob Agents Chemother 1981, 20:190-196.
105. Janicki RS, Garnham JC, Worland MC, et al. Comparison of erythromycin ethyl succinate, stearate and estolate treatments of group A streptococcal infections of the upper respiratory tract. Clin Pediatr (Phila) 1975, 14:1098-1107.
106. Ginsburg CM, McCracken GH, Crow SD, et al. Erythromycin therapy for group A streptococcal pharyngitis: results of a comparative study of the estolate and ethylsuccinate formulations. Am J Dis Child 1984, 138:536-539.
107. Osono T, Umezawa H Pharmacokinetics of macrolides, lincosamides and streptogramins. J Antimicrob Chemother 1985, 16(suppl A):151-166.
108. Bass JW, Steele RW, Wiebe RA, Dierdorff EP Erythromycin concentrations in middle ear exudates. Pediatrics 1971, 48:417-422.
109. Howard JE, Nelson JD, Clahsen J, Jackson LH Otitis media of infancy and early childhood: a double-blind study of four treatment regimens. Am J Dis Child 1976, 130:965-970.
110. Hand WL, Corwin RW, Steinberg TH, Grossman GD Uptake of antibiotics by human alveolar macrophages. Am Rev Respir Dis 1984, 129:933-937.
111. Miller MF, Martin JR, Johnson P, et al. Erythromycin uptake and accumulation by human polymorphonuclear leukocytes and efficacy of erythromycin in killing ingested Legionella pneumophila. J Infect Dis 1984, 149:714-718.
112. Romansky M, Nasou JP, Davis DS, et al. The treatment of 171 patients with erythromycin, including 132 with bacterial pneumonia. Antibiot Annu 1955-1956, 3:48-62.
113. Philipson A, Sabath LD, Charles D Transplacental passage of erythromycin and clindamycin. N Engl J Med 1973, 288:1219-1221.
114. Hammond J, Griffith RS Factors affecting the absorption and biliary excretion of erythromycin and two of its derivatives in humans. Clin Pharmacol Ther 1961, 2:308-312.
115. Mao J-H, Tardrew PL Demethylation of erythromycin by rabbit tissues in vitro. Biochem Pharmacol 1965, 14:1049-1058.
116. Kunin CM A guide to use of antibiotics in patients with renal disease: a table of recommended doses and factors governing serum levels. Ann Intern Med 1967, 67:151-158.
117. Handbook of Antimicrobial Therapy 2011, The Medical Letter on Drugs and Therapeutics, New Rochelle, NY.
118. Ellsworth AJ, Christensen DB, Volpone-McMahon MT Prospective comparison of patient tolerance to enteric-coated vs nonenteric-coated erythromycin. J Fam Pract 1990, 31:265-270.
119. Inman WH, Rawson NS Erythromycin estolate and jaundice. Br Med J (Clin Res Ed) 1983, 286:1954-1955.
120. Braun P Hepatotoxicity of erythromycin. J Infect Dis 1969, 119:300-306.
121. Tolman KG, Sannella JJ, Freston JW Chemical structure of erythromycin and hepatotoxicity. Ann Intern Med 1974, 81:58-60.
122. Pessayre D, Larrey D, Funck-Brentano C, Benhamou JP Drug interactions and hepatitis produced by some macrolide antibiotics. J Antimicrob Chemother 1985, 16(suppl A):181-194.
123. McCormack WM, George H, Donner A, et al. Hepatotoxicity of erythromycin estolate during pregnancy. Antimicrob Agents Chemother 1977, 12:630-635.
124. Sabath LD, Gerstein DA, Finland M Serum glutamic oxalacetic transaminase: false elevations during administration of erythromycin. N Engl J Med 1968, 279:1137-1139.
125. Carson JL, Strom BL, Duff A, et al. Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med 1993, 119:576-583.
126. Karmody CS, Weinstein L Reversible sensorineural hearing loss with intravenous erythromycin lactobionate. Ann Otol Rhinol Laryngol 1977, 86:9-11.
127. Eckman MR, Johnson T, Riess R Partial deafness after erythromycin [letter]. N Engl J Med 1975, 292:649.
128. Taylor R, Schofield IS, Ramos JM, et al. Ototoxicity of erythromycin in peritoneal dialysis patients. Lancet 1981, 2:935-936.
129. Haydon RC, Thelin JW, Davis WE Erythromycin ototoxicity: analysis and conclusions based on 22 case reports. Otolaryngol Head Neck Surg 1984, 92:678-684.
130. Swanson DJ, Sung RJ, Fine MJ, et al. Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am J Med 1992, 92:61-68.
131. Katapadi K, Kostandy G, Katapadi M, et al. A review of erythromycin-induced malignant tachyarrhythmia-torsades de pointes: a case report. Angiology 1997, 48:821-826.
132. Schoenenberger RA, Haefeli WE, Weiss P, Ritz RF Association of intravenous erythromycin and potentially fatal ventricular tachycardia with Q-T prolongation (torsades de pointes). BMJ 1990, 300:1375-1376.
133. Ray WA, Murray KT, Meredith S Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004, 351:1089-1096.
134. Daleau P, Lessard E, Groleau MF, Turgeon J Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation 1995, 91:3010-3016.
135. Gantz NM, Zawacki JK, Dickerson WJ, Bartlett JG Pseudomembranous colitis associated with erythromycin. Ann Intern Med 1979, 91:866-867.
136. Owens R, Donskey CJ, Gaynes RP, et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008, 46:S19-S31.
137. SanFilippo J Infantile hypertrophic pyloric stenosis related to ingestion of erythromycin estolate: a report of five cases. J Pediatr Surg 1976, 11:177-180.
138. Cooper WO, Griffin MR, Arbogast P, et al. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med 2002, 156:647-650.
139. Cooper WO, Ray WA, Griffin MR Prenatal prescription of macrolide antibiotics and infantile hypertrophic pyloric stenosis. Obstet Gynecol 2002, 100:101-106.
140. Ludden TM Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet 1985, 10:63-79.
141. Amsden GW Macrolides versus azalides: a drug interaction update. Ann Pharmacother 1995, 29:906-917.
142. Periti P, Mazzei T, Mini E, Novelli A Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992, 23:106-131.
143. Kim R The Medical Letter Handbook of Adverse Drug Interactions 2003, The Medical Letter on Drugs and Therapeutics, New Rochelle, NY.
144. Bass JW, Freitas BC, Freitas AD, et al. Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. Pediatr Infect Dis J 1998, 17:447-452.
145. Ohl ME, Spach DH Bartonella quintana and urban trench fever. Clin Infect Dis 2000, 31:131-135.
146. Aoyama T, Sunakawa K, Iwata S, et al. Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. J Pediatr 1996, 129:761-764.
147. Kuschner RA, Trofa AF, Thomas RJ, et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis 1995, 21:536-541.
148. Bailey RL, Arullendran P, Whittle HC, Mabey DC Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet 1993, 342:453-456.
149. Stout JE, Yu VL Legionellosis. N Engl J Med 1997, 337:682-687.
150. Martin DH, Mroczkowski TF, Dalu ZA, et al. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. The Azithromycin for Chlamydial Infections Study Group. N Engl J Med 1992, 327:921-925.
151. Girgis NI, Butler T, Frenck RW, et al. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance. Antimicrob Agents Chemother 1999, 43:1441-1444.
152. Khan WA, Seas C, Dhar U, et al. Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial. Ann Intern Med 1997, 126:697-703.
153. Mabey D, Peeling RW Lymphogranuloma venereum. Sex Transm Infect 2002, 78:90-92.
154. Steere AC Lyme disease. N Engl J Med 2001, 345:115-125.
155. Krause PJ, Lepore T, Sikand VK, et al. Atovaquone and azithromycin for the treatment of babesiosis. N Engl J Med 2000, 343:1454-1458.
156. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis 2007, 44:S27-S72.
157. Rasch J, Mogabgab WJ Therapeutic effect of erythromycin on Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother 1965, 5:399.
158. Shames JM, George RB, Holliday WB, et al. Comparison of antibiotics in the treatment of mycoplasmal pneumonia. Arch Intern Med 1970, 125:680-684.
159. Edelstein PH, Meyer RD Susceptibility of Legionella pneumophila to twenty antimicrobial agents. Antimicrob Agents Chemother 1980, 18:403-408.
160. Kuzman I, Soldo I, Schonwald S, Culig J Azithromycin for treatment of community acquired pneumonia caused by Legionella pneumophila: a retrospective study. Scand J Infect Dis 1995, 27:503-505.
161. Fields BS, Benson RF, Besser RE Legionella and Legionnaires' disease: 25 years of investigation. Clin Microbiol Rev 2002, 15:506-526.
162. Sprauer MA, Cochi SL, Zell ER, et al. Prevention of secondary transmission of pertussis in households with early use of erythromycin. Am J Dis Child 1992, 146:177-181.
163. Centers for Disease Control and Prevention Guidelines for the Control of Pertussis Outbreaks 2000, Centers for Disease Control and Prevention, Atlanta.
164. Centers for Disease Control and Prevention Sexually transmitted diseases treatment guidelines 2006. MMWR Morbid Mortal Wkly Rep 2006, 51(RR-11):1-100.
165. Anders BJ, Lauer BA, Paisley JW, Reller LB Double-blind placebo controlled trial of erythromycin for treatment of Campylobacter enteritis. Lancet 1982, 1:131-132.
166. Salazar-Lindo E, Sack RB, Chea-Woo E, et al. Early treatment with erythromycin of Campylobacter jejuni-associated dysentery in children. J Pediatr 1986, 109:355-360.
167. Taylor DN, Blaser MJ, Echeverria P, et al. Erythromycin-resistant Campylobacter infections in Thailand. Antimicrob Agents Chemother 1987, 31:438-442.
168. Clarke JS, Condon RE, Bartlett JG, et al. Preoperative oral antibiotics reduce septic complications of colon operations: results of prospective, randomized, double-blind clinical study. Ann Surg 1977, 186:251-259.
169. Stellato TA, Danziger LH, Gordon N, et al. Antibiotics in elective colon surgery. A randomized trial of oral, systemic, and oral/systemic antibiotics for prophylaxis. Am Surg 1990, 56:251-254.
170. Gasquet S, Maurin M, Brouqui P, et al. Bacillary angiomatosis in immunocompromised patients. AIDS 1998, 12:1793-1803.
171. Koehler JE, Tappero JW Bacillary angiomatosis and bacillary peliosis in patients infected with human immunodeficiency virus. Clin Infect Dis 1993, 17:612-624.
172. Kabir I, Khan WA, Haider R, et al. Erythromycin and trimethoprim-sulphamethoxazole in the treatment of cholera in children. J Diarrhoeal Dis Res 1996, 14:243-247.
173. Prunier AL, Malbruny B, Tande D, et al. Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolides. Antimicrob Agents Chemother 2002, 46:3054-3056.
174. Fenton LJ, Light IJ Congenital syphilis after maternal treatment with erythromycin. Obstet Gynecol 1976, 47:492-494.
175. Zinner SH, Sabath LD, Casey JI, Finland M Erythromycin and alkalinisation of urine in the treatment of urinary-tract infections due to gram-negative bacilli. Lancet 1971, 1:1267-1268.
176. Bahal N, Nahata MC The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother 1992, 26:46-55.
177. Drehobl MA, De Salvo MC, Lewis DE, Breen JD Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 2005, 128:2230-2237.
178. Piscitelli S, Danziger LH, Rodvold KA Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 1992, 11:137-152.
179. Neu HC Clinical microbiology of azithromycin. Am J Med 1991, 91:12S-18S.
180. Versalovic J, Shortridge D, Kibler K, et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996, 40:477-480.
181. Taylor DE, Ge Z, Purych D, et al. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrob Agents Chemother 1997, 41:2621-2628.
182. Nash KA, Inderlied CB Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob Agents Chemother 1995, 39:2625-2630.
183. Hardy DJ, Guay DR, Jones RN Clarithromycin, a unique macrolide: a pharmacokinetic, microbiological, and clinical overview. Diagn Microbiol Infect Dis 1992, 15:39-53.
184. Credito KL, Lin G, Pankuch GA, et al. Susceptibilities of Haemophilus influenzae and Moraxella catarrhalis to ABT-773 compared to their susceptibilities to 11 other agents. Antimicrob Agents Chemother 2001, 45:67-72.
185. Tateda K, Ishii Y, Matsumoto T, et al. Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: suppression of virulence factors and stress response. J Infect Chemother 2000, 6:1-7.
186. Skindersoe ME, Alhede M, Phipps R, et al. Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008, 52:3648-3663.
187. Fitzgeorge RB, Lever S, Baskerville A A comparison of the efficacy of azithromycin and clarithromycin in oral therapy of experimental airborne Legionnaires' disease. J Antimicrob Chemother 1993, 31(suppl E):171-176.
188. Bohte R, van't Wout JW, Lobatto S, et al. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1995, 14:182-187.
189. Yew WW, Piddock LJ, Li MS, et al. In-vitro activity of quinolones and macrolides against mycobacteria. J Antimicrob Chemother 1994, 34:343-351.
190. Steele-Moore L, Stark K, Holloway WJ In vitro activities of clarithromycin and azithromycin against clinical isolates of Mycobacterium avium-M. intracellulare. Antimicrob Agents Chemother 1999, 43:1530.
191. Perronne C, Gikas A, Truffot-Pernot C, et al. Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. Antimicrob Agents Chemother 1991, 35:1356-1359.
192. Bermudez LE, Petrofsky M, Kolonoski P, Young LS Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. Antimicrob Agents Chemother 1998, 42:180-183.
193. Derouin F, Chastang C Activity in vitro against Toxoplasma gondii of azithromycin and clarithromycin alone and with pyrimethamine. J Antimicrob Chemother 1990, 25:708-711.
194. Gan VN, McCarty JM, Chu SY, Carr R Penetration of clarithromycin into middle ear fluid of children with acute otitis media. Pediatr Infect Dis J 1997, 16:39-43.
195. Sanche S, Williams K, Stein K Cerebrospinal fluid pen-etration of clarithromycin and 14-hydroxyclarithromycin (abstract 728). Thirty-third Interscience Conference on Antimicrobial Agents and Chemotherapy 1993, New Orleans, October.
196. Anderson R, Joone G, van Rensburg CE An in-vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. J Antimicrob Chemother 1988, 22:923-933.
197. Schentag JJ, Ballow CH Tissue-directed pharmacokinetics. Am J Med 1991, 91:5S-11S.
198. Hopkins S Clinical toleration and safety of azithromycin. Am J Med 1991, 91:40S-45S.
199. Foulds G, Hilligoss DM, Henry EB, Gerber N The effects of an antacid or cimetidine on the serum concentrations of azithromycin. J Clin Pharmacol 1991, 31:164-167.
200. Ballow CH, Amsden GW Azithromycin: the first azalide antibiotic. Ann Pharmacother 1992, 26:1253-1261.
201. Jaruratanasirikul S, Hortiwakul R, Tantisarasart T, et al. Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. Antimicrob Agents Chemother 1996, 40:825-826.
202. Chandrupatla S, Demetris AJ, Rabinovitz M Azithromycin-induced intrahepatic cholestasis. Dig Dis Sci 2002, 47:2186-2188.
203. Wallace RJ, Brown BA, Griffith DE Drug intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis 1993, 16:215-221.
204. Kolkman W, Groeneveld JH, Baur HJ, Verschuur HP Ototoxicity induced by clarithromycin. Ned Tijdschr Geneeskd 2002, 146:1743-1745.
205. Shaffer D, Singer S, Korvick J, Honig P Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis 2002, 35:197-200.
206. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012, 366:1881-1890.
207. Med Lett Drugs Ther 2013, 55:28.
208. FDA Drug Safety Communication: azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms http://www.fda.gov/drugs/drugsafety/ucm341822.htm.
209. Harris S, Hilligoss DM, Colangelo PM, et al. Azithromycin and terfenadine: lack of drug interaction. Clin Pharmacol Ther 1995, 58:310-315.
210. Polis MA, Piscitelli SC, Vogel S, et al. Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997, 41:1709-1714.
211. Vance E, Watson-Bitar M, Gustavson L, Kazanjian P Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. Antimicrob Agents Chemother 1995, 39:1355-1360.
212. Nawarskas JJ, McCarthy DM, Spinler SA Digoxin toxicity secondary to clarithromycin therapy. Ann Pharmacother 1997, 31:864-866.
213. Hammerschlag MR, Roblin PM, Bebear CM Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens. J Antimicrob Chemother 2001, 48(suppl T1):25-31.
214. Bisno AL, Gerber MA, Gwaltney JM, et al. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America. Clin Infect Dis 2002, 35:113-125.
215. Still JG, Hubbard WC, Poole JM, et al. Comparison of clarithromycin and penicillin VK suspensions in the treatment of children with streptococcal pharyngitis and review of currently available alternative antibiotic therapies. Pediatr Infect Dis J 1993, 12:S134-S141.
216. Hooton TM A comparison of azithromycin and penicillin V for the treatment of streptococcal pharyngitis. Am J Med 1991, 91:23S-26S.
217. Schaad UB, Kellerhals P, Altwegg M Azithromycin versus penicillin V for treatment of acute group A streptococcal pharyngitis. Pediatr Infect Dis J 2002, 21:304-308.
218. Kaplan EL, Gooch WM, Notario GF, Craft JC Macrolide therapy of group A streptococcal pharyngitis: 10 days of macrolide therapy (clarithromycin) is more effective in streptococcal eradication than 5 days (azithromycin). Clin Infect Dis 2001, 32:1798-1802.
219. Hamill J Multicentre evaluation of azithromycin and penicillin V in the treatment of acute streptococcal pharyngitis and tonsillitis in children. J Antimicrob Chemother 1993, 31(suppl E):89-94.
220. Casey JR, Pichichero ME Higher dosages of azithromycin are more effective in treatment of Group A streptococcal tonsillopharyngitis. Clin Infect Dis 2005, 40:1748-1755.
221. Ghirga G, Palazzi C, Ghirga P, et al. Inefficacy of a 3-day course of azithromycin in preventing acute rheumatic fever after group A streptococcal infection (scarlet fever) in an 8-year-old child. J Pediatr 1999, 134:123-124.
222. Aronovitz G A multicenter, open label trial of azithromycin vs. amoxicillin/clavulanate for the management of acute otitis media in children. Pediatr Infect Dis J 1996, 15:S15-S19.
223. Arguedas A, Loaiza C, Rodriguez F, et al. Comparative trial of 3 days of azithromycin versus 10 days of clarithromycin in the treatment of children with acute otitis media with effusion. J Chemother 1997, 9:44-50.
224. Bochud PY, Calandra T, Moreillon P, et al. Breakthrough Streptococcus pneumoniae meningitis during clarithromycin therapy for acute otitis media. Eur J Clin Microbiol Infect Dis 2001, 20:136-137.
225. Gikas A, Kofteridis DP, Manios A, et al. Newer macrolides as empiric treatment for acute Q fever infection. Antimicrob Agents Chemother 2001, 45:3644-3646.
226. Principi N, Esposito S, Blasi F, Allegra L Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired lower respiratory tract infections. Clin Infect Dis 2001, 32:1281-1289.
227. Socan M Treatment of atypical pneumonia with azithromycin: comparison of a 5-day and a 3-day course. J Chemother 1998, 10:64-68.
228. Gleason PP, Meehan TP, Fine JM, et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999, 159:2562-2572.
229. Houck PM, MacLehose RF, Niederman MS, Lowery JK Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest 2001, 119:1420-1426.
230. Mufson MA, Stanek RJ Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978-1997. Am J Med 1999, 107:34S-43S.
231. Waterer GW, Somes GW, Wunderink RG Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001, 161:1837-1842.
232. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003, 36:389-395.
233. Martinez FJ Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients. Clin Infect Dis 2004, 38(suppl 4):5328-5340.
234. Lin E, Stanek RJ, Mufson MA Lack of synergy of erythromycin combined with penicillin or cefotaxime against Streptococcus pneumoniae in vitro. Antimicrob Agents Chemother 2003, 47:1151-1153.
235. Johansen HK, Jensen TG, Dessau RB, et al. Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo. J Antimicrob Chemother 2000, 46:973-980.
236. Langley JM, Halperin SA, Boucher FD, et al. Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. Pediatrics 2004, 114:e96-e101.
237. Tiwari T, Murphy TV, Moran J Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. MMWR Recomm Rep 2005, 54(RR-14):1-16. National Immunization Program, CDC.
238. Hoppe JE, Haug A Treatment and prevention of pertussis by antimicrobial agents (Part II). Infection 1988, 16:148-152.
239. American Academy of Pediatrics Pertussis 2000, American Academy of Pediatrics, Elk Grove Village, IL. L.K. Pickering (Ed.).
240. Meier A, Heifets L, Wallace RJ, et al. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rRNA mutations in a clonal population. J Infect Dis 1996, 174:354-360.
241. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med 1994, 121:905-911.
242. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996, 335:384-391.
243. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med 1996, 335:392-398.
244. Aberg JA, Williams PL, Liu T, et al. A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team. J Infect Dis 2003, 187:1046-1052.
245. Tabbara KF, Abu-el-Asrar A, al-Omar O, et al. Single-dose azithromycin in the treatment of trachoma: a randomized, controlled study. Ophthalmology 1996, 103:842-846.
246. Stamm WE, Hicks CB, Martin DH, et al. Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men: a randomized double-blind study. JAMA 1995, 274:545-549.
247. Newman LM, Moran JS, Workowski KA Update on the management of gonorrhea in adults in the United States. Clin Infect Dis 2007, 44:S84-S101.
248. Ulmer H, Beckerling A, Gatz G Recent use of proton pump inhibitor-based therapies for the eradication of H. pylori: a broad data review. Helicobacter 2003, 8:95-104.
249. Marshall B Sequential therapy for Helicobacter pylori: a worthwhile effort for your patients. Ann Intern Med 2008, 148:962-963.
250. Tompkins DS, Perkin J, Smith C Failed treatment of Helicobacter pylori infection associated with resistance to clarithromycin. Helicobacter 1997, 2:185-187.
251. Buckley MJ, Xia HX, Hyde DM, et al. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. Dig Dis Sci 1997, 42:2111-2115.
252. Hoge CW, Gambel JM, Srijan A, et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998, 26:341-345.
253. Wallace RJ, Tanner D, Brennan PJ, Brown BA Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Intern Med 1993, 119:482-486.
254. Vemulapalli RK, Cantey JR, Steed LL, et al. Emergence of resistance to clarithromycin during treatment of disseminated cutaneous Mycobacterium chelonae infection: case report and literature review. J Infect 2001, 43:163-168.
255. Ji B, Jamet P, Perani EG, et al. Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy. J Infect Dis 1993, 168:188-190.
256. Dattwyler RJ, Grunwaldt E, Luft BJ Clarithromycin in treatment of early Lyme disease: a pilot study. Antimicrob Agents Chemother 1996, 40:468-469.
257. Luft BJ, Dattwyler RJ, Johnson RC, et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans: a double-blind, randomized, controlled trial. Ann Intern Med 1996, 124:785-791.
258. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment and prevention of Lyme disease, human granulocytic anaplasmosis and babeseosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006, 43:1089-1134.
259. Andersen SL, Ager AL, McGreevy P, et al. Efficacy of azithromycin as a causal prophylactic agent against murine malaria. Antimicrob Agents Chemother 1994, 38:1862-1863.
260. Anderson SL, Berman J, Kuschner R, et al. Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers. Ann Intern Med 1995, 123:771-773.
261. Andersen SL, Oloo AJ, Gordon DM, et al. Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clin Infect Dis 1998, 26:146-150.
262. Taylor WR, Richie TL, Fryauff DJ, et al. Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis 1999, 28:74-81.
263. Ohrt C, Willingmyre GD, Lee P, et al. Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. Antimicrob Agents Chemother 2002, 46:2518-2524.
264. Noedl H, Krudsood S, Chalermratana K, et al. Azithromycin combination therapy with artesunate or quinine for the treatment of uncomplicated Plasmodium falciparum malaria in adults: a randomized, phase 2 clinical trial in Thailand. Clin Infect Dis 2006, 43:1264-1271.
265. Kalilani L, Mofolo I, Chaponda M, et al. A randomized controlled pilot trial of azithromycin or artesunate added to sulfadoxine-pyramethamine as treatment for malaria in pregnant women. PloS One 2007, 2:e1166.
266. Dionisio D, Orsi A, Sterrantino G, et al. Chronic cryptosporidiosis in patients with AIDS: stable remission and possible eradication after long-term, low dose azithromycin. J Clin Pathol 1998, 51:138-142.
267. Blanshard C, Shanson DC, Gazzard BG Pilot studies of azithromycin, letrazuril and paromomycin in the treatment of cryptosporidiosis. Int J STD AIDS 1997, 8:124-129.
268. Holmberg SD, Moorman AC, Von Bargen JC, et al. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. HIV Outpatient Study (HOPS) Investigators. JAMA 1998, 279:384-386.
269. Hansson GK, Libby P The immune response in atherosclerosis: a double-edged sword. Nature Rev Immunol 2006, 6:508-519.
270. Schneider CA, Diedrichs H, Riedel KD, et al. In vivo uptake of azithromycin in human coronary plaques. Am J Cardiol 2000, 86:789-791.
271. Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997, 96:404-407.
272. Cercek B, Shah PK, Noc M, et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet 2003, 361:809-813.
273. Muhlestein JB, Anderson JL, Carlquist JF, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 2000, 102:1755-1760.
274. O'Connor CM, Dunne MW, Pfeffer MA, et al. Azithromycin for the secondary prevention of coronary heart disease events. The WIZARD Study: a randomized controlled trial. JAMA 2003, 290:1459-1466.
275. Jesperson CM, Als-Nielson B, Damgaard M, et al. Randomized placebo controlled trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006, 332:22-27.
276. Wolter J, Seeney S, Bell S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002, 57:212-216.
277. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M Long term azithromycin in children with cystic fibrosis: a randomized, placebo-controlled crossover trial. Lancet 2002, 360:978-984.
278. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003, 290:1749-1756.
279. Clement A, Tamalet A, Leroux E, et al. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 2006, 61:895-902.
280. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011, 365:689-698.
281. Giamarellos-Bourboulis EJ, Pechère J-C, Routsi C, et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 2008, 46:1157-1164.
282. Spyridaki A, Raftogiannis M, Antonopoulou A, et al. Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by gram-negative bacteria: results from a randomized study. Antimicrob Agents Chemo 2012, 56:3819-3825.
283. Giamarellos-Bourboulis EJ Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents 2008, 31:12-20.
284. Renna M, Schaffner C, Brown K, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 2011, 121:3553-3563.
285. Bonnefoy A, Girard AM, Agouridas C, Chantot JF Ketolides lack inducibility properties of MLS(B) resistance phenotype. J Antimicrob Chemother 1997, 40:85-90.
286. Douthwaite S Structure-activity relationships of ketolides vs. macrolides. Clin Microbiol Infect 2001, 7:11-17.
287. Hansen LH, Mauvais P, Douthwaite S The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Mol Microbiol 1999, 31:623-631.
288. Champney WS, Tober CL Structure-activity relationships for six ketolide antibiotics. Curr Microbiol 2001, 42:203-210.
289. Malathum K, Coque TM, Singh KV, Murray BE In vitro activities of two ketolides, HMR 3647 and HMR 3004, against gram-positive bacteria. Antimicrob Agents Chemother 1999, 43:930-936.
290. Jalava J, Kataja J, Seppala H, Huovinen P In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species. Antimicrob Agents Chemother 2001, 45:789-793.
291. Schulin T, Wennersten CB, Moellering RC, Eliopoulos GM In-vitro activity of the new ketolide antibiotic HMR 3647 against gram-positive bacteria. J Antimicrob Chemother 1998, 42:297-301.
292. Wootton M, Bowker KE, Janowska A, et al. In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and beta-haemolytic streptococci. J Antimicrob Chemother 1999, 44:445-453.
293. Giovanetti E, Montanari MP, Marchetti F, Varaldo PE In vitro activity of ketolides telithromycin and HMR 3004 against Italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility. J Antimicrob Chemother 2000, 46:905-908.
294. Okamoto H, Miyazaki S, Tateda K, et al. Comparative in vitro activity of telithromycin (HMR 3647), three macrolides, amoxicillin, cefdinir and levofloxacin against gram-positive clinical isolates in Japan. J Antimicrob Chemother 2000, 46:797-802.
295. Barry AL, Fuchs PC, Brown SD In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae. Antimicrob Agents Chemother 1998, 42:2138-2140.
296. Hoban DJ, Zhanel GG, Karlowsky JA In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Diagn Microbiol Infect Dis 1999, 35:37-44.
297. Hoppe JE, Bryskier A In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine). Antimicrob Agents Chemother 1998, 42:965-966.
298. Bebear CM, Renaudin H, Bryskier A, Bebear C Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas. Antimicrob Agents Chemother 2000, 44:1980-1982.
299. Roblin PM, Hammerschlag MR In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob Agents Chemother 1998, 42:1515-1516.
300. Schulin T, Wennersten CB, Ferraro MJ, et al. Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob Agents Chemother 1998, 42:1520-1523.
301. Rastogi N, Goh KS, Berchel M, Bryskier A In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4. Antimicrob Agents Chemother 2000, 44:2848-2852.
302. Namour F, Wessels DH, Pascual MH, et al. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob Agents Chemother 2001, 45:170-175.
303. Pharma A Ketek (telithromycin) briefing document for the FDA anti-infective drug products advisory committee [executive summary] 2001, Aventis Pharma, Bridgewater, NJ. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3919B1_01_Aventis-KETEK.pdf.
304. Clay KD, Hanson JS, Pope SD, et al. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Int Med 2006, 144:415-420.
305. Dore DD, DiBello JR, Lapane KL Telithromycin use and spontaneous reports of hepatotoxicity. Drug Saf 2007, 30:697-703.
306. Perrot X, Bernard N, Vial C, et al. Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment. Neurology 2006, 67:2256-2258.
307. McGehee R, Smith CB, Wilcox C, et al. Comparative studies of antibacterial activity in vitro and absorption and excretion of lincomycin and clindamycin. Am J Med Sci 1968, 256:279-292.
308. Weisblum B Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother 1995, 39:577-585.
309. Siberry GK, Tekle T, Carroll K, et al. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003, 37:1257-1260.
310. Daurel C, Huet C, Dhalluin A, et al. Differences in the potential for selection of clindamycin-resistant mutants between inducible erm(A) and erm(C) Staphylococcus aureus genes. J Clin Microbiol 2008, 46:546-550.
311. LaPlante KL, Leonard SN, Andes DR, et al. Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. Antimicrob Agents Chemother 2008, 52:2156-2162.
312. Poehlisgaard J, Pfister P, Bottger EC, Douthwaite S Molecular mechanisms by which rRNA mutations confer resistance to clindamycin. Antimicrob Agents Chemother 2005, 49:1553-1555.
313. Leclercq R, Brisson-Noel A, Duval J, Courvalin P Phenotypic expression and genetic heterogeneity of lincosamide inactivation in Staphylococcus spp. Antimicrob Agents Chemother 1987, 31:1887-1891.
314. Archard A, Villers C, Pichereau V, Leclercq R New Inu(C) gene conferring resistance to lincomycin by nucleotidylation in Streptococcus agalactiae UCN36. Antimicrob Agents Chemother 2005, 49:2716-2719.
315. Low DE, de Azavedo J, Weiss K, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob Agents Chemother 2002, 46:1295-1301.
316. Aldridge KE, Ashcraft D, Cambre K, et al. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother 2001, 45:1238-1243.
317. Liu C-Y, Huang Y-T, Liao C-H, et al. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother 2008, 52:3161-3168.
318. Snydman DR, Jacobus NV, McDermott LA, et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother 2008, 51:1649-1655.
319. Snydman DR, Jacobus NV, McDermott LA, et al. Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009. Anaerobe 2011, 17:147-151.
320. Schaumann R, Funke M, Janssen E, Rodloff AC In vitro activities of clindamycin, imipenem, metronidazole and piperacillin-tazobactam against susceptible and resistant isolates of Bacteroides fragilis evaluated by kill kinetics. Antimicrob Agents Chemother 2012, 56:3413-3416.
321. Rasmussen BA, Bush K, Tally FP Antimicrobial resistance in anaerobes. Clin Infect Dis 1997, 24(suppl 1):S110-S120.
322. Sutter VL In vitro susceptibility of anaerobes: comparison of clindamycin and other antimicrobial agents. J Infect Dis 1977, 135(suppl):S7-S12.
323. Nelson CT, Mason EO, Kaplan SL Activity of oral antibiotics in middle ear and sinus infections caused by penicillin-resistant Streptococcus pneumoniae: implications for treatment. Pediatr Infect Dis J 1994, 13:585-589.
324. Cornaglia G, Ligozzi M, Mazzariol A, et al. Rapid increase of resistance to erythromycin and clindamycin in Streptococcus pyogenes in Italy, 1993-1995. The Italian Surveillance Group for Antimicrobial Resistance. Emerg Infect Dis 1996, 2:339-342.
325. Brook I, Gober AE, Leyva F In vitro and in vivo effects of penicillin and clindamycin on expression of group A beta-hemolytic streptococcal capsule. Antimicrob Agents Chemother 1995, 39:1565-1568.
326. Gemmell CG, Peterson PK, Schmeling D, et al. Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest 1981, 67:1249-1256.
327. Sriskandan S, McKee A, Hall L, Cohen J Comparative effects of clindamycin and ampicillin on superantigenic activity of Streptococcus pyogenes. J Antimicrob Chemother 1997, 40:275-277.
328. Sawai J, Hasegawa T, Kamimura T, et al. Growth phase-dependent effect of clindamycin on production of exoproteins by Streptococcus pyogenes. Antimicrob Agents Chemother 2007, 51:461-467.
329. Stevens DL, Yan S, Bryant AE Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis 1993, 167:1401-1405.
330. Tenover FC, McAllister S, Fosheim G, et al. J Clin Microbiol 2008, 46:2837-2841.
331. Huang H, Flynn NM, King JH, et al. Comparisons of community-associated methicillin-resistant Staphylococcus aureus (MRSA) and hospital-associated MRSA infections in Sacramento, California. J Clin Microbiol 2006, 44:2423-2427.
332. David MZ, Glikman D, Crawford SE, et al. What is community-associated methicillin-resistant Staphylococcus aureus?. J Infect Dis 2008, 197:1235-1243.
333. Sande MA, Johnson ML Antimicrobial therapy of experimental endocarditis caused by Staphylococcus aureus. J Infect Dis 1975, 131:367-375.
334. Nastro LJ, Finegold SM Bactericidal activity of five anti-microbial agents against Bacteroides fragilis. J Infect Dis 1972, 126:104-107.
335. Stevens D, Ma Y, Salmi DB, et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007, 195:202-211.
336. Pfefferkorn ER, Nothnagel RF, Borotz SE Parasiticidal effect of clindamycin on Toxoplasma gondii grown in cultured cells and selection of a drug-resistant mutant. Antimicrob Agents Chemother 1992, 36:1091-1096.
337. Seaberg LS, Parquette AR, Gluzman IY, et al. Clindamycin activity against chloroquine-resistant Plasmodium falciparum. J Infect Dis 1984, 150:904-911.
338. DeHaan RM, Metzler CM, Schellenberg D, Vandenbosch WD Pharmacokinetic studies of clindamycin phosphate. J Clin Pharmacol 1973, 13:190-209.
339. Fass RJ, Saslaw S Clindamycin: clinical and laboratory evaluation of parenteral therapy. Am J Med Sci 1972, 263:368-382.
340. Townsend RJ, Baker RP Pharmacokinetic comparison of three clindamycin phosphate dosing schedules. Drug Intell Clin Pharm 1987, 21:279-281.
341. Panzer JD, Brown DC, Epstein WL, et al. Clindamycin levels in various body tissues and fluids. J Clin Pharmacol New Drugs 1972, 12:259-262.
342. Prokesch RC, Hand WL Antibiotic entry into human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1982, 21:373-380.
343. Joiner KA, Lowe BR, Dzink JL, Bartlett JG Antibiotic levels in infected and sterile subcutaneous abscesses in mice. J Infect Dis 1981, 143:487-494.
344. McCall CE, Steigbigel NH, Finland M Lincomycin: activity in vitro and absorption and excretion in normal young men. Am J Med Sci 1967, 254:144-155.
345. Kager L, Liljeqvist L, Malmborg AS, Nord CE Effect of clindamycin prophylaxis on the colonic microflora in patients undergoing colorectal surgery. Antimicrob Agents Chemother 1981, 20:736-740.
346. Brown RB, Martyak SN, Barza M, et al. Penetration of clindamycin phosphate into the abnormal human biliary tract. Ann Intern Med 1976, 84:168-170.
347. Joshi AM, Stein RM Altered serum clearance of intravenously administered clindamycin phosphate in patients with uremia. J Clin Pharmacol 1974, 14:140-144.
348. Williams DN, Crossley K, Hoffman C, Sabath LD Parenteral clindamycin phosphate: pharmacology with normal and abnormal liver function and effect on nasal staphylococci. Antimicrob Agents Chemother 1975, 7:153-158.
349. Bartlett JG Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin Infect Dis 2008, 46(suppl 1):S4-S11.
350. Tedesco FJ Clindamycin and colitis: a review. J Infect Dis 1977, 135(suppl):S95-S98.
351. Kelly CP, LaMont JT Clostridium difficile-more difficult than ever. N Engl J Med 2008, 359:1932-1940.
352. Owens R, Donskey CJ, Gaynes RP, et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008, 46:S19-S31.
353. Dial S, Kezouh A, Dascal A, et al. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ 2008, 179:767-772.
354. Meadowcroft AM, Diaz PR, Latham GS Clostridium difficile toxin-induced colitis after use of clindamycin phosphate vaginal cream. Ann Pharmacother 1998, 32:309-311.
355. Elmore M, Rissing JP, Rink L, Brooks GF Clindamycin-associated hepatotoxicity. Am J Med 1974, 57:627-630.
356. Weinstein WM, Onderdonk AB, Bartlett JG, et al. Anti-microbial therapy of experimental intraabdominal sepsis. J Infect Dis 1975, 132:282-286.
357. diZerega G, Yonekura L, Roy S, et al. A comparison of clindamycin-gentamicin and penicillin-gentamicin in the treatment of post-cesarean section endomyometritis. Am J Obstet Gynecol 1979, 134:238-242.
358. Solomkin JS, Dellinger EP, Christou NV, Busuttil RW Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann Surg 1990, 212:581-591.
359. Sirinek KR, Levine BA A randomized trial of ticarcillin and clavulanate versus gentamicin and clindamycin in patients with complicated appendicitis. Surg Gynecol Obstet 1991, 172:30-35.
360. Condon RE, Walker AP, Sirinek KR, et al. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 1995, 21:544-550.
361. Bartlett JG, Gorbach SL Treatment of aspiration pneumonia and primary lung abscess: penicillin G vs clindamycin. JAMA 1975, 234:935-937.
362. Levison ME, Mangura CT, Lorber B, et al. Clindamycin compared with penicillin for the treatment of anaerobic lung abscess. Ann Intern Med 1983, 98:466-471.
363. Bartlett JG, Gorbach SL Penicillin or clindamycin for primary lung abscess?. Ann Intern Med 1983, 98:546-548.
364. Gudiol F, Manresa F, Pallares R, et al. Clindamycin vs penicillin for anaerobic lung infections. High rate of penicillin failures associated with penicillin-resistant Bacteroides melaninogenicus. Arch Intern Med 1990, 150:2525-2529.
365. Stevens DL, Maier KA, Mitten JE Effect of antibiotics on toxin production and viability of Clostridium perfringens. Antimicrob Agents Chemother 1987, 31:213-218.
366. Stevens DL, Maier KA, Laine BM, Mitten JE Comparison of clindamycin, rifampin, tetracycline, metronidazole, and penicillin for efficacy in prevention of experimental gas gangrene due to Clostridium perfringens. J Infect Dis 1987, 155:220-228.
367. Watanakunakorn C Clindamycin therapy of Staphylococcus aureus endocarditis: clinical relapse and development of resistance to clindamycin, lincomycin and erythromycin. Am J Med 1976, 60:419-425.
368. Leyden JJ, Berger RS, Dunlap FE, et al. Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. Am J Clin Dermatol 2001, 2:33-39.
369. Parry MF, Rha CK Pseudomembranous colitis caused by topical clindamycin phosphate. Arch Dermatol 1986, 122:583-584.
370. Schmitt C, Sobel JD, Meriwether C Bacterial vaginosis: treatment with clindamycin cream versus oral metronidazole. Obstet Gynecol 1992, 79:1020-1023.
371. Kurkinen-Raty M, Vuopala S, Koskela M, et al. A randomised controlled trial of vaginal clindamycin for early pregnancy bacterial vaginosis. BJOG 2000, 107:1427-1432.
372. McDonald HM, O'Loughlin JA, Vigneswaran R, et al. Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomised, placebo controlled trial. Br J Obstet Gynaecol 1997, 104:1391-1397.
373. Carey JC, Klebanoff MA, Hauth JC, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 2000, 342:534-540.
374. Ugwumadu A, Manyonda I, Reid F, Hay P Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet 2003, 361:983-988.
375. Rouphael NG, O'Donnell JA, Bhatnagar J, et al. Clostridium difficile-associated diarrhea: an emerging threat to pregnant women. Am J Obstet Gynecol 2008, 198:635.e1-635.e6.
376. Dannemann B, McCutchan JA, Israelski D, et al. Treatment of toxoplasmic encephalitis in patients with AIDS: a randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med 1992, 116:33-43.
377. Katlama C, De Wit S, O'Doherty E, et al. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 1996, 22:268-275.
378. Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS: a double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med 1996, 124:792-802.
379. Benfield T, Atzori C, Miller RF, Helweg-Larsen J Second-line salvage treatment of AIDS-associated Pneumocystis jirovecii pneumonia. A case series and systematic review. J Acquir Defic Syndr 2008, 48:63-67.
380. Kremsner PG, Radloff P, Metzger W, et al. Quinine plus clindamycin improves chemotherapy of severe malaria in children. Antimicrob Agents Chemother 1995, 39:1603-1605.
381. Wittner M, Rowin KS, Tanowitz HB, et al. Successful chemotherapy of transfusion babesiosis. Ann Intern Med 1982, 96:601-604.
382. Ramharter M, Oyakhirome S, Klein Klouwenberg P, et al. Artesunate-clindamycin versus quinine-clindamycin in the treatment of Plasmodium falciparum malaria: a randomized controlled trial. Clin Infect Dis 2005, 40:1777-1784.
383. Brook I, Hirokawa R Treatment of patients with a history of recurrent tonsillitis due to group A beta-hemolytic streptococci: a prospective randomized study comparing penicillin, erythromycin, and clindamycin. Clin Pediatr (Phila) 1985, 24:331-336.
384. Orrling A, Stjernquist-Desatnik A, Schalen C, Kamme C Clindamycin in persisting streptococcal pharyngotonsillitis after penicillin treatment. Scand J Infect Dis 1994, 26:535-541.
385. American Academy of Pediatrics, Committee on Infectious Diseases Severe invasive group A streptococcal infections: a subject review. Pediatrics 1998, 101:136-140.
386. Stevens DL, Madaras-Kelly KJ, Richards DM In vitro antimicrobial effects of various combinations of penicillin and clindamycin against four strains of Streptococcus pyogenes. Antimicrob Agents Chemother 1998, 42:1266-1268.
387. Leclercq R, Courvalin P Resistance to macrolides and related antibiotics in Streptococcus pneumoniae. Antimicrob Agents Chemother 2002, 46:2727-2734.
388. Leclercq R, Courvalin P Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria. Antimicrob Agents Chemother 1991, 35:1273-1276.
389. Leclercq R Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002, 34:482-492.
390. Richter SS, Hellman KP, Beekmann SE, et al. Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003. Clin Infect Dis 2005, 41:599-608a.
391. Haight T, Finland M Observations on mode of action of erythromycin. Proc Soc Exp Biol Med 1952, 81:188-193.
392. Sabath L, Gerstein DA, Loder PB, et al. Excretion of erythromycin and its enhanced activity in urine against gram-negative bacilli with alkalinization. J Lab Clin Med 1968, 72:916-923.
393. Pfaller MA, Farrell DJ, Sader HS, et al. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Clin Infect Dis 2012, 55(suppl 3):S187-S193.
394. Hyde TB, Gay K, Stephens DS, et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001, 286:1857-1862.
395. Farrell DJ, File TM, Jenkins SG Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000-2004) of the PROTEKT US Study. J Clin Micro 2007, 45:290-293.
396. Green MD, Beall B, Marcon MJ, et al. Multicentre surveillance of the prevalence and molecular epidemiology of macrolide resistance among pharyngeal isolates of group A streptococci in the USA. J Antimicrobial Chemotherapy 2006, 57:1240-1243.
397. Villasenor-Sierra A, Katahira E, Jaramillo-Valdivia AN, et al. Phenotypes and genotypes of erythromycin-resistant pyogenes strains isolated from invasive and non-invasive infections from Mexico and the USA during 1999-2010. Int J Infect Dis 2012, 16:e178-e181.
398. Sader HS, Flamm RK, Farrell DJ, et al. Activity analyses of Staphylococcal isolates from pediatric, adult and elderly patients: AWARE Ceftaroline surveillance program. Clin Infect Dis 2012, 55:S181-S186.
399. Haight TH, Finland FM Laboratory and clinical studies on erythromycin. N Engl J Med 1952, 247:227-232.
400. Garrod L The erythromycin group of antibiotics. Br Med J 1957, 2:57-63.
401. Catnach SM, Fairclough PD Erythromycin and the gut. Gut 1992, 33:397-401.
402. Kudoh S, Azuma A, Yamamoto M, et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998, 157:1829-1832.
403. Keicho N, Kudoh S Diffuse panbronchiolitis: the role of macrolides in therapy. Am J Resp Med 2002, 1:119-131.
404. Aoki Y, Kao PN Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells. Antimicrob Agents Chemother 1999, 43:2678-2684.
405. Osono T, Umezawa H Pharmacokinetics of macrolides, lincosamides and streptogramins. J Antimicrob Chemother 1985, 16(suppl A):151-166.
406. Handbook of Antimicrobial Therapy 2011, The Medical Letter on Drugs and Therapeutics, New Rochelle, NY.
407. Braun P Hepatotoxicity of erythromycin. J Infect Dis 1969, 119:300-306.
408. Ray WA, Murray KT, Meredith S Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004, 351:1089-1096.
409. Amsden GW Macrolides versus azalides: a drug interaction update. Ann Pharmacother 1995, 29:906-917.
410. Fields BS, Benson RF, Besser RE Legionella and Legionnaires' disease: 25 years of investigation. Clin Microbiol Rev 2002, 15:506-526.
411. Bahal N, Nahata MC The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother 1992, 26:46-55.
412. Drehobl MA, De Salvo MC, Lewis DE, Breen JD Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 2005, 128:2230-2237.
413. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012, 366:1881-1890.
414. Med Lett Drugs Ther 2013, 55:28.
415. Bisno AL, Gerber MA, Gwaltney JM, et al. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America. Clin Infect Dis 2002, 35:113-125.
416. Hooton TM A comparison of azithromycin and penicillin V for the treatment of streptococcal pharyngitis. Am J Med 1991, 91:23S-26S.
417. Drugs for peptic ulcer disease and GERD. Treat Guidel Med Lett 2011, 9:55-60.
418. Healy DP Macrolide immunomodulation of chronic respiratory diseases. Curr Infect Dis Rep 2007, 9:7-13.
419. Bryskier A, Denis A Ketolides: novel antibacterial agents designed to overcome resistance to erythromycin A within gram positive cocci. Macrolide Antibiotics 2002, 97-140. Birkhauser Verlag, Boston. W. Schonfeld, H.A. Kirst (Eds.).
420. Pharma A Ketek (telithromycin) briefing document for the FDA anti-infective drug products advisory committee [executive summary] 2001, Aventis Pharma, Bridgewater, NJ. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3919B1_01_Aventis-KETEK.pdf.
421. McGehee R, Smith CB, Wilcox C, et al. Comparative studies of antibacterial activity in vitro and absorption and excretion of lincomycin and clindamycin. Am J Med Sci 1968, 256:279-292.
422. Siberry GK, Tekle T, Carroll K, et al. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003, 37:1257-1260.
423. Stevens DL, Gibbons AE, Bergstrom R, Winn V The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988, 158:23-28.
424. Duncan IB Development of lincomycin resistance by staphylococci. Antimicrobial Agents Chemother 1967, 7:723-729.
425. Nastro LJ, Finegold SM Bactericidal activity of five antimicrobial agents against Bacteroides fragilis. J Infect Dis 1972, 126:104-107.
426. Nicholas P, Meyers BR, Levy RN, Hirschman SZ Concentration of clindamycin in human bone. Antimicrob Agents Chemother 1975, 8:220-221.
427. Shehab N, Patel PR, Srinivasin A, Budnitz DS Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis 2008, 47735-47743.